Exact Sciences secures colorectal cancer test rights from Freenome in a $75M agreement with up to $700M milestone payouts.

Under the agreement, Exact Sciences will pay Freenome an upfront cash payment of $75m that is payable by this November.

EXAS) on Wednesday reported a loss of $1.2 million in its second quarter. The Madison, Wisconsin-based company said it had a ...

Full-year 2025 revenue and adjusted EBITDA guidance were raised, reflecting strong commercial execution and new product launches. These 10 stocks could mint the next wave of millionaires › Exact ...

MADISON, Wis. -- Exact Sciences is laying off 4% of its overall workforce, including 80 positions in Madison. Approximately ...

Exact Sciences bought the rights to Freenome's blood-based colon cancer test. The news could spark Exact Sciences stock.

Analysts anticipate Exact Sciences to report an earnings per share (EPS) of $0.02. Anticipation surrounds Exact Sciences's ...

Madison-based Exact Sciences is cutting about 4% of its overall workforce, impacting about 200 positions in Wisconsin.

NasdaqCM:EXAS 1 Year Share Price vs Fair Value Explore Exact Sciences's Fair Values from the Community and select ...

Exact Sciences is paying $75 million for exclusive rights to a blood-based "liquid biopsy" screening test from rival firm Freenome ...

Exact Sciences’ gross margin for the quarter was 69%, with adjusted gross margin at 72%. The company reported operating cash flow of $89 million and free cash flow of $47 million, ending the quarter ...